Vanguard Group
DMK

Vanguard Group’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Vanguard Group’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33,990
Closed -$23.8K – 4533
2023
Q4 		$23.8K Buy
33,990
+3,900
+13% +$2.26K ﹤0.01% 4430
2023
Q3 		$20.7K Sell
30,090
-820
-3% -$1.05K ﹤0.01% 4496
2023
Q2 		$74.5K Sell
30,910
-61,718
-67% -$264K ﹤0.01% 4414
2023
Q1 		$751K Hold
92,628
– – ﹤0.01% 3995
2022
Q4 		$1.1M Buy
92,628
+47
+0.1% +$537 ﹤0.01% 3880
2022
Q3 		$1.29M Hold
92,581
– – ﹤0.01% 3920
2022
Q2 		$3.25M Hold
92,581
– – ﹤0.01% 3586
2022
Q1 		$3.7M Sell
92,581
-546
-0.6% -$23.4K ﹤0.01% 3669
2021
Q4 		$3.94M Buy
93,127
+135
+0.1% +$8.42K ﹤0.01% 3740
2021
Q3 		$6.32M Buy
92,992
+2,794
+3% +$204K ﹤0.01% 3510
2021
Q2 		$6.94M Buy
90,198
+8,319
+10% +$507K ﹤0.01% 3401
2021
Q1 		$5.39M Buy
81,879
+52,397
+178% +$4.08M ﹤0.01% 3494
2020
Q4 		$1M Buy
29,482
+1,576
+6% +$70.1K ﹤0.01% 3827
2020
Q3 		$1.53M Buy
27,906
+770
+3% +$45.6K ﹤0.01% 3557
2020
Q2 		$1.02M Buy
27,136
+190
+0.7% +$6.5K ﹤0.01% 3614
2020
Q1 		$673K Hold
26,946
– – ﹤0.01% 3605
2019
Q4 		$1.32M Sell
26,946
-612
-2% -$29.7K ﹤0.01% 3563
2019
Q3 		$1.36M Buy
27,558
+1,968
+8% +$141K ﹤0.01% 3564
2019
Q2 		$2.33M Buy
25,590
+1,108
+5% +$135K ﹤0.01% 3433
2019
Q1 		$3.62M Buy
24,482
+9,289
+61% +$1.8M ﹤0.01% 3258
2018
Q4 		$2.39M Sell
15,193
-8,200
-35% -$1.57M ﹤0.01% 3320
2018
Q3 		$5.73M Buy
23,393
+4,981
+27% +$1.18M ﹤0.01% 3182
2018
Q2 		$4.12M Buy
18,412
+111
+0.6% +$29.7K ﹤0.01% 3268
2018
Q1 		$4.48M Buy
18,301
+618
+3% +$162K ﹤0.01% 3193
2017
Q4 		$5.45M Buy
17,683
+1,511
+9% +$497K ﹤0.01% 3099
2017
Q3 		$5.91M Buy
16,172
+2,701
+20% +$958K ﹤0.01% 3052
2017
Q2 		$4.9M Buy
13,471
+2,446
+22% +$732K ﹤0.01% 3090
2017
Q1 		$3.28M Buy
11,025
+1,256
+13% +$317K ﹤0.01% 3217
2016
Q4 		$2.15M Buy
9,769
+1,936
+25% +$388K ﹤0.01% 3341
2016
Q3 		$1.88M Buy
7,833
+3,036
+63% +$631K ﹤0.01% 3418
2016
Q2 		$940K Buy
4,797
+860
+22% +$396K ﹤0.01% 3619
2016
Q1 		$1.69M Buy
3,937
+193
+5% +$69K ﹤0.01% 3441
2015
Q4 		$1.42M Buy
3,744
+94
+3% +$29.5K ﹤0.01% 3518
2015
Q3 		$1.01M Buy
3,650
+59
+2% +$16.4K ﹤0.01% 3631
2015
Q2 		$1.06M Buy
3,591
+216
+6% +$65.3K ﹤0.01% 3648
2015
Q1 		$931K Buy
3,375
+2,518
+294% +$1.09M ﹤0.01% 3650
2014
Q4 		$370K Buy
857
+546
+176% +$173K ﹤0.01% 3806
2014
Q3 		$102K Buy
+311
New +$91.2K ﹤0.01% 3952

Other funds holding DMK

Clear Point Advisors
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
Old Point Trust & Financial Services N A
Old Point Trust & Financial Services N A Newport News, Virginia $329M AUM 22.88% 1-Year Est. Return

Vanguard Group's DMK Position: Q1 2024 in Review

Vanguard Group sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 33,990 shares — an estimated $23.8K sold.

Vanguard Group first reported a position in DMK in Q3 2014 and held it in 38 quarters. The position peaked at $6.94M in Q2 2021. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.

  • Vanguard Group reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 33,990 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $23.8K.
  • Vanguard Group first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2014 and held it in 38 quarters.
  • Vanguard Group's DMK Pharmaceuticals Corporation Common Stock position peaked at $6.94M in Q2 2021.
  • 3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.